Author

P. Timms

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:metabolism & bioenergetics· 1 Assay:proteomics· 1

Frequent Co-Authors

A. C. Williams· 2 shared O. J. Sansom· 2 shared T. J. Collard· 2 shared A. C. Chambers· 1 shared A. J. Hoskin· 1 shared A. K. Holt· 1 shared A. K. Najumudeen· 1 shared C. Parker· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. C. Williams

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Aspirin reprogrammes colorectal cancer cell metabolism and sensitises to glutaminase inhibition

A. K. Holt, A. K. Najumudeen, A. J. Hoskin, D. N. Legge, E. M. H. Mortensson, D. J. Flanagan, N. Jones, M. Kollareddy, T. J. Collard, P. Timms, O. J. Sansom, A. C. Williams, E. E. Vincent

This study shows aspirin reprograms colorectal cancer cell metabolism and increases sensitivity to glutaminase inhibition, suggesting potential for improved metabolic therapies in CRC.

bioRxiv · Aug 24, 2022Cancer Biology

Loss of BCL-3 sensitises colorectal cancer cells to DNA damage, revealing a role for BCL-3 in double strand break repair by homologous recombination

C. Parker, A. C. Chambers, D. Flanagan, T. J. Collard, G. Ngo, D. M. Baird, P. Timms, R. G. Morgan, O. J. Sansom, A. C. Williams

This study shows that loss of BCL-3 increases DNA damage and reduces homologous recombination in colorectal cancer cells, suggesting BCL-3 as a potential target to enhance DNA damage therapy response.

bioRxiv · Aug 3, 2021 · PreprintCancer Biology